Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)

Creg J. Workman and Dario A. A. Vignali


http://www.jimmunol.org/content/174/2/688

---

**References**

This article *cites 56 articles*, 30 of which you can access for free at: http://www.jimmunol.org/content/174/2/688.full#ref-list-1

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions**

Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)¹

Creg J. Workman and Dario A. A. Vignali²

Lymphocyte homeostasis is a central biological process that is tightly regulated. However, its molecular and cellular control is poorly understood. We show that aged mice deficient in lymphocyte activation gene 3 (LAG-3), an MHC class II binding CD4 homologue, have twice as many T cells as wild-type controls. CD4⁺ and CD8⁺ LAG-3-deficient T cells showed enhanced homeostatic expansion in lymphopenic hosts, which was abrogated by ectopic expression of wild-type LAG-3, but not by a signaling-defective mutant. In addition, in vivo treatment with anti-LAG-3 mAb resulted in enhanced T cell expansion to a level comparable to that in LAG-3-deficient cells. This deregulation of T cell homeostasis also resulted in the expansion of multiple cell types, including B cells, macrophages, granulocytes, and dendritic cells. Lastly, regulatory T cells were dependent on LAG-3 for their optimal control of T cell homeostasis. Our data suggest that LAG-3 negatively regulates T cell homeostasis by regulatory T cell-dependent and independent mechanisms. The Journal of Immunology, 2005, 174: 688–695.

Materials and Methods

Mice

The following mice were used: LAG-3⁻/⁻ (obtained from Y.-H. Chen, Stanford University, Palo Alto, CA, with permission from C. Benoist and D. Mathis, Joslin Diabetes Center, Boston, MA) (32), C57BL/6 (The Jackson Laboratory), B6.PL-Thy1a/Cy (Thy1.1 congenic; The Jackson Laboratory), RAG-1⁻/⁻ (The Jackson Laboratory) (34), OT-II TCR transgenic mice (provided by S. Schoenberger, La Jolla Institute for Allergy and Immunology, La Jolla, CA, with permission from W. Heath, Walter and Eliza Hall Institute, Parkville, Australia (35), B6.129-Abr⁻/⁻ N5 mice (MHC-II⁻/⁻; provided by P. Doherty, St. Jude Children’s Research Hospital, Memphis, TN), and OT-I (OVA) TCR transgenic mice (The Jackson Laboratory) (36). Genome-wide microsatellite analysis demonstrated that 97% of the 88 genetic markers tested for LAG-3⁻/⁻ mice were derived from C57BL/6 mice (Charles River Laboratories). LAG-3⁻/⁻, OT-II-LAG-3⁻/⁻, and OT-ILLAG-3⁻/⁻ colonies were maintained at St. Jude Animal Resource Center. All animal experiments were performed in an Association for Assessment of Laboratory Animal Care-accredited, specific pathogen-free facility, following national, state, and institutional guidelines. Animal protocols were approved by the St. Jude institutional animal care and use committee.

LAG-3 constructs and retroviral transduction

LAG-3 constructs were produced using recombinant PCR as previously described (37). The LAG-3 wild-type (WT) and LAG-3ΔKIEELE (LAG-3 with a deletion of the conserved KIEELE motif in the cytoplasmic tail) have been described previously (31). LAG-3 constructs were cloned into a murine stem cell virus-based retroviral vector, which contained an internal
The average number of BrdU incorporation was assessed with a biotinylated rat anti-LAG-3 mAb (C9B7W, H57-597), V\(_{\text{H}11002}\), and LAG-3 \((\text{HL3}; \text{DC marker}), \text{and CD244.2 (2B4; pan NK cell marker)}. \) LAG-3 expression was assessed by FACS. The cells were allowed to rest for 2 additional days, then 5 \(\times\) 10\(^6\) cells were transferred into RAG-1\(^{-/-}\) mice via the tail vein. In some experiments, adoptive transfer recipients were treated with either anti-LAG-3 (C9B7W, IgG1 \(\kappa\); 100 or 50 \(\mu\)g on day 0; 50 or 25 \(\mu\)g on day 3) (29) or an isotype control (R3-34; BD Pharmingen; 200 \(\mu\)g on day 0; 100 \(\mu\)g on day 3).

Adoptive transfer experiments

T and/or B cells from the spleens of age-matched (within 4 wk) mice were positively sorted by FACS, negatively sorted by MACS, or both. For MACS purifications, splenocytes were stained for TCR\(\alpha\beta\), CD4, and CD8 expression and sorted by positive selection on a MoFlo (DakoCytomation). For negative MACS purification, splenocytes were stained with PE-conjugated or biotinylated anti-B220, anti-Gr1, anti-Mac1, anti-TER119 (erythrocytes), anti-CD49b (NK cells), and anti-CD8 (for negative purification of CD4\(^+\) T cells only). The cells were then incubated with magnetic beads coupled with anti-PE Ab or streptavidin and negatively sorted on an autoMACS (Miltenyi Biotec) to 90–95% purity. For purification of CD4\(^+\)CD25\(^+\) cells, splenocytes were first negatively sorted on an autoMACS, then the CD4\(^+\) T cells were stained for CD25 and separated by FACS using the MoFlo. Unless otherwise stated, 5 \(\times\) 10\(^6\) cells were transferred into RAG-1\(^{-/-}\) mice via the tail vein. Fifteen days posttransfer, the mice were killed by CO\(_2\) inhalation, and spleens were removed.

Results

LAG-3\(^{-/-}\) mice have more T cells

WT C57BL/6 mice have a constant number of \(\alpha\beta^+\) T cells from 5–52 wk of age (Fig. 1A). As previously reported, young (5-wk-
old) LAG-3−/− mice have normal T cell numbers (32). However, the number of αβ T cells increases in LAG-3−/− mice to ~2-fold higher than that in WT mice at ~16 wk of age (Fig. 1A). This difference is highly significant (p < 0.005) given the tight homeostatic regulation of αβ T cell numbers in WT mice and the very low SE. Both CD4+ and CD8+ cells were increased in LAG-3−/− mice, but the CD4:CD8 ratio was unchanged, except in 1-year-old mice (Fig. 1B and data not shown). Interestingly, T cells were not significantly elevated in bone marrow or axillary, inguinal, and popliteal lymph nodes (Fig. 1C). However, T cell numbers were clearly elevated in Peyer’s patches from LAG-3−/− mice, indicating that these observations were not restricted to the spleen, but did differ between different lymphoid organs. LAG-3−/− mice transgenic for OT-II TCR (OVA 326–339-specific, H-2Aβ-restricted) (35) also had an increased number of CD4+ Vα2+ T cells compared with WT control OT-II transgenic mice, except that this difference was evident at 5 wk of age (Fig. 1D). The increased cell number observed in LAG-3−/− mice was consistent with an ~50% increase in the number of dividing BrdU+ cells in vivo, although the percentage was largely unchanged (Fig. 1, E and F). It is important to note that the differences in cell numbers observed between LAG-3−/− and WT mice were highly similar and reproducible. The absence of LAG-3 did not appear to have any significant effect on the cell surface phenotype of T cells from LAG-3−/− mice or the ratio of naive, memory, or regulatory T cells (data not shown). Taken together, these data suggest that LAG-3 may help regulate T cell numbers in mice.

It has been reported that cytokines are important in the maintenance of T cell homeostasis, in particular IL-7, as well as other cytokines that signal through the common γ-chain (14, 15). However, analysis of serum from 12-wk-old LAG-3−/+ and LAG-3−/− mice did not reveal differences in IL-7 levels (data not shown). The presence of 16 additional cytokines was also tested, but no differences were found (IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12(p40), IL-12(p70), IL-17, KC, MIP-1α, RANTES, GM-CSF, IFN-γ and TNF-α) (data not shown). Because IL-15 levels were not tested, it is possible that this cytokine may be involved in homeostatic control.

Enhanced homeostatic expansion of LAG-3−/− T cells

To determine whether LAG-3 influences the homeostatic expansion of T cells in a lymphopenic environment, purified T cells were adoptively transferred into Rag-1−/− mice, which lack T and B cells, and the T cell number in the spleen was determined 15 days posttransfer. There was a 2.6-fold increase in the number of LAG-3−/− T cells compared with that in the WT control (Fig. 2A). Remarkably, there was virtually no LAG-3 expressed on WT T cells despite the clear effect that the absence of LAG-3 has on T cell expansion (data not shown). Increased expansion of both CD4+ and CD8+ T cells was observed, demonstrating that both cell types were equally affected by the absence of LAG-3. There were no obvious differences in cell surface phenotype or the percentage of apoptotic cells, as determined by annexin V staining, between LAG-3−/− and LAG-3−/+ T cells (data not shown). As previously reported, these cells display a memory-like phenotype, with increased expression of CD44 and reduced CD62L (42–44). However, very few cells expressed the activation marker CD69. Importantly, this increased cell number was not due to the selective expansion of memory cells, because a comparable difference was seen after transfer of sorted naive CD44lowLAG-3−/− and LAG-3−/+ T cells (Fig. 2B).

To ensure that the increased expansion of LAG-3−/− T cells observed in Rag-1−/− mice was independent of Ag specificity and to further assess the effect of LAG-3 on CD4+ vs CD8+ T cell expansion, we used purified T cells from OT-I (OVA 257–264-specific, H-2Kb-restricted) (36) and OT-II transgenic mice. OT-II transgenic T cells were of particular interest because they have previously been shown to undergo poor homeostatic expansion in irradiated mice (45). In Rag-1−/− mice, WT CD4+ Vα2 OT-II T cells do expand, albeit poorly (Fig. 2C). In contrast, this did not
3. On day 7, the number of CD4$^+$/H11001$^+$/H9262$^+$ B cells were rested for 10 days, and Vα2$^+$CD4$^+$GFP$^+$ transgenic T cells were sorted by FACS. After an additional 2-day rest, 5 $\times$ 10$^6$ cells were transferred into RAG-1$^-$ mice. Fifteen days posttransfer, the mice were killed, the spleens were removed, and the number of Vα2$^+$CD4$^+$GFP$^+$ transgenic T cells was determined. Data represent the mean $\pm$ SE of two independent experiments with 8–10 mice per group. B. In vivo manipulation of T cell homeostasis by anti-LAG-3 mAb treatment. LAG-3$^{-/-}$ and LAG-3$^{+/-}$ T cells were negatively sorted by MACS. T cells (5 $\times$ 10$^6$) plus anti-LAG-3 (C9B7W; 100 or 50 µg), or PBS were injected into RAG-1$^-$ mice via the tail vein. Mice were given a second treatment of the appropriate Ab at half the original dose (50 or 25 µg) or PBS i.v. on day 3. On day 7, the number of CD4$^+$ T cells in the spleen was determined. Data represent the mean $\pm$ SE of two independent experiments with two to eight mice per group.

apply to T cells from LAG-3$^{-/-}$ OT-II transgenic mice, which expanded vigorously in lymphopenic hosts to numbers 3.1-fold higher than those of WT T cells by 15 days posttransfer. This enhanced expansion was not due to a nonspecifically induced hyperactivated state, because no proliferation was observed after restimulation of these cell types constitutively express LAG-3 in WT mice (29).

Similar studies with H-2K$^b$-restricted OT-I T cells again emphasize that CD4$^+$ and CD8$^+$ T cells are comparably affected. The number of LAG-3$^{-/-}$ CD8$^+$ Vα2$^+$ OT-I transgenic T cells recovered from RAG-1$^{-/-}$ mice was 4.3-fold higher than that of WT control OT-I T cells 7 days posttransfer (Fig. 2E). We have previously shown that ligation of LAG-3 by MHC class II is required for LAG-3 function in vitro (31). To address this issue in vivo, we transferred OTILLAG-3$^{+/+}$ and OTILLAG-3$^{-/-}$ transgenic T cells into RAG-1$^{-/-}$/H9253/H9254 mice. As predicted, both OTILLAG-3$^{+/+}$ and OTILLAG-3$^{-/-}$ T cells expanded equivalently in RAG-1$^{-/-}$/H9253/H9254 mice 7 days posttransfer (Fig. 2E). Furthermore, OTILLAG-3$^{+/+}$ T cells expanded more after transfer into RAG-1$^{-/-}$/H9253/H9254 vs RAG-1$^{-/-}$ mice (2.9-fold). These data suggest that ligation of MHC class II molecules is required for LAG-3 to control homeostatic expansion.

T cell homeostasis is controlled by a KIEELE motif in the cytoplasmic domain of LAG-3

Were the defects observed due to the absence of LAG-3 or were they caused by disruption of a closely linked gene by the original targeting strategy? Furthermore, was LAG-3 directly or indirectly involved in this process? To address these questions, we transduced LAG-3$^{-/-}$ OT-II T cells with murine stem cell virus-based retrovirus that contained either WT LAG-3 or a signaling-defective mutant, LAG-3.$\Delta\text{KM}$, which lacks a conserved KIEELE motif (31). The vector also contained an internal ribosomal entry site and GFP cassette to facilitate analysis of transduced cells (38). LAG-3$^{-/-}$ and LAG-3$^{+/+}$ OT-II T cells were also transduced with an empty vector/GFP-alone control. It is important to note that the transduction efficiencies of WT LAG-3, LAG-3.$\Delta\text{KM}$, and empty vector/GFP-alone were equivalent (data not shown). Transduced cells were sorted on the top 30–40% of GFP$^+$ cells and transferred into RAG-1$^{-/-}$ recipients. Fifteen days posttransfer, the number of GFP$^+$/OT-II T cells was determined. As expected, the control LAG-3$^{-/-}$ T cells transduced with GFP alone expanded more than the WT GFP$^+$ T cells (2.6-fold; Fig. 3A). Ectopic expression of LAG-3 reduced the number of OT-II T cells to a level comparable to that of the WT control, whereas expression of the LAG-3 signaling-defective mutant had no effect on homeostatic expansion. These data demonstrate that LAG-3 is directly involved in the regulation of T cell homeostasis and that this requires the KIEELE motif in the cytoplasmic domain of LAG-3 (31).

LAG-3-mediated control of T cell homeostasis can be blocked in vivo by anti-LAG-3 mAb treatment

We have previously described a mAb to murine LAG-3 that blocks its function in vitro without interfering with its ability to bind to MHC class II molecules (29). RAG-1$^{-/-}$ recipients of LAG-3$^{-/-}$ and LAG-3$^{+/+}$ CD4$^+$ T cells were treated with purified anti-LAG-3 or an irrelevant rat IgG1 control on days 0 and 3. The data show that anti-LAG-3 treatment blocked LAG-3 function in vivo, resulting in accelerated homeostatic expansion of WT T cells to a value comparable to the number of LAG-3$^{-/-}$ cells in control PBS-treated mice (Fig. 3B). Despite the dramatic effect of the Ab on blocking LAG-3 function, the mechanism of Ab blocking is still under investigation. Although our previous in vitro results suggest that the mAb is not blocking LAG-3 interaction with MHC class II, we cannot exclude the possibility that it is doing so in vivo (45). Another possibility is that the Ab is blocking the interaction of LAG-3 with another molecule we have yet to identify. Although the exact mechanism of Ab blocking is unclear, the results are striking with negligible background. Taken together, these data suggest that anti-LAG-3 treatment may allow for the therapeutic manipulation of homeostasis.

Cells that express LAG-3 regulate the expansion of cells that do not

More extensive analysis of 16-wk-old LAG-3$^{-/-}$ mice revealed a generalized increase in many cell types. The numbers of yel$^+$ T cells and CD244$^+$ NK cells were significantly increased in LAG-3$^{-/-}$ mice (Fig. 4A). This might be expected given that $\sim$20% of these cell types constitutively express LAG-3 in WT mice (29).
However, we were surprised to find that several other cell types, such as B220+ B cells, Gr-1+ granulocytes, Mac-1+ macrophages, and CD11c+ DC, none of which expresses LAG-3 (26, 27, 29), were also increased in LAG-3−/− mice (Fig. 4, A–C). The increased B cell number observed in LAG-3−/− mice was also reflected in a 2-fold increase in the number of BrdU+ cells (Fig. 4B).

A direct role for T cells in mediating this multilineage increase was implied by a 2-fold increase in the number of αβ+ host-derived cells observed in RAG-1−/− recipients of LAG-3−/− T cells (Fig. 4E). These data imply that an alteration in the homeostatic control of T cells due to the absence of LAG-3 may directly alter the control of other leukocyte cell types. To test this directly, B cells were co transferred with either LAG-3−/− or WT T cells into RAG-1−/− mice. As seen previously, there was a 5.0-fold increase in the number of LAG-3−/− T cells compared with WT control cells when transferred with B cells (Fig. 4F). In the presence of WT T cells, the number of B cells recovered from the spleen 7 days posttransfer was identical with that in mice receiving B cells alone. In contrast, there was a 2.8-fold increase in the number of B cells recovered from LAG-3−/− T cell recipients.

To date, our data suggest that there is not a generalized activated phenotype that causes the multilineage expansion. This idea is further supported by some preliminary studies that suggest that the ability of CD11c+ DCs from LAG-3−/− or LAG-3+/+ mice to stimulate T cells is comparable (data not shown), although additional studies would be required to analyze this issue more extensively. Taken together, these data provide a direct demonstration that the generalized multilineage increase is due to the deregulation of T cells lacking LAG-3.

*Treg cells control T cell homeostasis via LAG-3*

How does LAG-3 regulate T cell homeostasis? First, signaling through LAG-3 may directly control homeostatic T cell expansion or induce the secretion of molecules that cause enhanced T cell expansion. Second, LAG-3 may function indirectly via another cell population. Because CD4+CD25+ Treg cells have been shown to control T cell homeostasis, it is possible that LAG-3 is required for optimal Treg cell function. These possibilities were tested directly in cotransfer experiments. LAG-3−/−Thy1.2+ T cells and LAG-3−/−Thy1.1+ T cells were transferred alone or together into RAG-1−/− recipients. The number of αβ+ CD4+ or CD8+ T cells in the spleen was determined 7 days posttransfer, and LAG-3 genotype was distinguished on the basis of Thy1 isotype expression. Previous studies have shown that the number of cells transferred can affect the extent of homeostatic expansion (20). To ensure that this factor did not complicate data interpretation, we chose a cell dose that could be doubled without significantly increasing the number of cells recovered (Fig. 5A). These experiments showed that transfer of either 5 × 10^6 or 1 × 10^7 cells resulted in the recovery of comparable numbers of cells even though there was still a 2-fold increase in the number of BrdU+. Fifteen days later, the recipients were killed, and cell number was determined.

As seen previously, there was a 5.0-fold increase of either 5 × 10^6 B cells and/or donor-derived B cells (Fig. 4B). We were intrigued to find that the proportion of each DC subset was altered. Although the number of myeloid CD8+ B220− DCs and lymphoid CD8+B220− DCs was largely unaffected, there was a substantial increase in the number and percentage of plasmacytoid CD8+/−B220+ DCs in LAG-3−/− mice (Fig. 4, C and D).

A direct role for T cells in mediating this multilineage increase was implied by a 2-fold increase in the number of αβ+ host-derived cells observed in RAG-1−/− recipients of LAG-3−/− T cells (Fig. 4E). These data imply that an alteration in the homeostatic control of T cells due to the absence of LAG-3 may directly alter the control of other leukocyte cell types. To test this directly, B cells were co transferred with either LAG-3−/− or WT T cells into RAG-1−/− mice. As seen previously, there was a 5.0-fold increase in the number of LAG-3−/− T cells compared with WT control cells when transferred with B cells (Fig. 4F). In the presence of WT T cells, the number of B cells recovered from the spleen 7 days posttransfer was identical with that in mice receiving B cells alone. In contrast, there was a 2.8-fold increase in the number of B cells recovered from LAG-3−/− T cell recipients.

To date, our data suggest that there is not a generalized activated phenotype that causes the multilineage expansion. This idea is further supported by some preliminary studies that suggest that the
increase in the number of LAG-3−/− vs LAG-3+/+ T cells recovered (Fig. 5A). Cotransfer of both populations clearly demonstrated that LAG-3−/− T cells prevented LAG-3−/− T cells from expanding. These data clarify an important point. The ability of LAG-3−/− T cells to control the expansion of LAG-3−/− T cells suggests an indirect effect, perhaps involving Treg cells.

This possibility was tested directly by cotransfer experiments with naïve CD4+CD25− T cells in the presence or the absence of CD4+CD25− Treg cells. LAG-3−/− and LAG-3−/− T cells were first negatively sorted by MACS to isolate CD4+ T cells, then positively sorted by FACS to separate CD4+CD25+ and CD4+CD25− T cell populations. CD4+CD25− T cells were transferred alone or with CD4+CD25+ Treg cells of the same or opposing genotype (15% of the total cell number transferred). Two important observations were made. First, the enhanced expansion of LAG-3−/− T cells occurs independently of Treg cells (no Treg, 2.3-fold difference; LAG-3−/− Treg, 3.8-fold difference; LAG-3−/− Treg, 1.9-fold difference). This suggests that LAG-3 can affect homeostatic T cell expansion directly. Second, Treg cells from LAG-3+/+ mice clearly reduced homeostatic proliferation of both LAG-3+/+ and LAG-3−/− T cells (Fig. 5B). However, Treg cells sorted from LAG-3−/− mice did not reduce LAG-3+/+ or LAG-3−/− CD4+CD25− T cell expansion. This suggests that LAG-3 is required for optimal Treg cell control of homeostatic expansion.

**Discussion**

Our data clearly show that LAG-3 negatively regulates the homeostatic expansion of T cells. Previous studies have suggested that CTLA-4 and TGF-β may also be negative regulators of T cell homeostasis (18, 19, 46). However, T cells from mice that lack CTLA-4 or carry a dominant negative TGF-β receptor have an activated phenotype; therefore, it is unclear whether the increased T cell number in these mice is due to a true breakdown of homeostasis or simply the continuous proliferation of activated T cells (16, 17, 19). In contrast, T cells from LAG-3−/− mice are indistinguishable, in terms of cell surface markers, from their WT counterparts. Thus, LAG-3 may be a true regulator of T cell homeostasis. Although it is clear that LAG-3 does not completely prevent T cell expansion, it may serve as a molecular brake to control homeostatic proliferation.

As previously reported (32) and shown in this study, no difference in T cell numbers are seen in younger mice. However, a significant increase in T cells in LAG-3−/− mice is seen in older mice. Three possibilities are worth consideration. First, one possible explanation is that the slightly increased turnover of LAG-3−/− T cells is not evident until the mice are ~3 mo old and is too subtle to be seen in BrdU experiments. Second, Treg cells are not required for homeostatic control until after 5 wk of age. Third, LAG-3−/− Treg cells may be able to control T cell homeostasis up to 5 wk of age due to their residual regulatory activity, which becomes insufficient after this time. This latter possibility may be supported by our observations with OT-ILLAG-3−/− mice, which display a significantly increased T cell number at 5 wk, because these mice have a much lower number of Treg cells and thus manifest deregulated homeostasis at a younger age. It is also noteworthy that the differences observed between LAG-3+/+ and LAG-3−/− mice are almost lost by 52 wk of age. The reason for this is unknown, but it is possible that the expanded T cells die off due to exhaustion, leaving a more homeostatically balanced population.

LAG-3 appears to function both directly and indirectly to control T cell homeostasis. Our data support a direct role for LAG-3 in regulating homeostatic T cell expansion independently of CD4+CD25+ Treg cells (see Figs. 2E, 3A, and 5B). Importantly, the enhanced expansion of purified LAG-3−/− CD8+ T cells, which were devoid of CD4+CD25+ Treg cells, in lymphopenic mice also supports this premise (see Fig. 2E). However, as yet we cannot rule out the possibility that a small percentage of CD25− T cells have regulatory activity or that cells within the expanding population acquire regulatory activity and indirectly affect T cell expansion. These data suggest that LAG-3 may impart regulatory potential on any cell in which it is expressed. This idea is supported by our demonstration that ectopic expression of LAG-3 confers regulatory potential on activated T cells (unpublished observations) (47), a property that to date has only been demonstrated with the forkhead/winged helix transcription factor (48, 49).

Our data also support an indirect role for LAG-3 in regulating T cell homeostasis. In the absence of LAG-3, CD4+CD25+ Treg cells are completely unable to control T cell expansion, suggesting
that LAG-3 is required for $T_{reg}$ control of T cell homeostasis. Recently, a more general role for LAG-3 in $T_{reg}$ function has been suggested (47). A comparative analysis of gene expression arrays from Ag-specific CD4$^+$ T cells differentiating to either an effector/memory or a regulatory phenotype was performed to identify molecules that were selectively expressed on $T_{reg}$ cells. LAG-3 was found to be the most differentially expressed gene of those whose identity is currently known. This analysis revealed that LAG-3 is differentially expressed on induced $T_{reg}$ cells, and this correlated with their in vitro regulatory activity. Importantly, the regulatory activity in this system could also be blocked with anti-LAG-3 mAb in vitro and in vivo. Thus, using two very distinct, but complimentary, experimental systems, we provide strong data suggesting that LAG-3 is required for maximal $T_{reg}$ function.

Despite the clear effect that LAG-3 has on T cell homeostasis, only low levels of LAG-3 could be detected on WT T cells. Interestingly, we have recently shown that there is a 10-fold increase in LAG-3 mRNA in CD4$^+$CD25$^+$ compared with CD4$^+$CD25$^-$ T cells (47). Thus, there is an apparent discrepancy between the minimal LAG-3 cell surface expression observed on resting CD4$^+$CD25$^+$ T cells and cells undergoing homeostatic expansion and the mRNA data. An explanation for this may come from our recent observation that LAG-3 is readily cleaved from the cell surface (50). Thus, transient, low level expression of LAG-3 may be sufficient to mediate its effect, perhaps emphasizing the importance of its high affinity for MHC class II molecules (29, 51). Likewise, given that LAG-3 appears to be required for $T_{reg}$ control of homeostasis, LAG-3 may only need to be transiently expressed on the small population of regulatory T cells to have a significant effect on homeostatic T cell expansion. Collectively, these data suggest that cell surface expression of LAG-3 is carefully regulated and thus is difficult to detect on the surface of resting $T_{reg}$ cells. Despite this low level expression, it is very evident from our data that signaling through the cytoplasmic domain of LAG-3 is essential for it to mediate its negative regulatory function (Fig. 3A) (31). Indeed, we have recently shown that ectopic expression of LAG-3 is sufficient to confer both cell intrinsic and extrinsic regulatory activity (49). Thus, transient expression on either the expanding CD25$^-$ population or the CD25$^+$ regulatory cells could be sufficient to mediate homeostatic control. Identification of molecules that bind to the KIEEL motif in LAG-3 is clearly required to gain further insight into LAG-3 function.

Our data clearly show that LAG-3$^{-/-}$ T cells mediate the enhanced homeostatic expansion of multiple cell types. This is evident from the increased numbers of all cell types analyzed in LAG-3$^{-/-}$ mice and data from the adoptive transfer experiments. Given that $T_{reg}$ cells are unable to control T cell expansion in these studies, it is possible that they may also directly or indirectly regulate other cell types. Alternatively, the increased number of total T cells and/or DCs may also influence multiple cell types. Although we did not see differences in cytokine levels in sera from LAG-3$^{-/-}$ and LAG-3$^{+/+}$ mice, we cannot exclude the possibility that such differences do exist, but that these are consumed by the increased number of T cells in LAG-3$^{-/-}$ mice. It is evident, however, that these increased cell numbers are not due to cells having an activated state, implying a true alteration of the homeostatic balance in these mice.

One intriguing finding was the differential expansion of different DC subsets in the LAG-3$^{-/-}$ mice. Although the number of myeloid CD8$^+$B220$^-$ DCs and lymphoid CD8$^+$B220$^-$ DCs was largely unaffected, there was a substantial increase in the number of plasmacytoid CD8$^{+/+}$B220$^+$ DCs in LAG-3$^{-/-}$ mice. The reason for this is unclear, but it is worth noting that plasmacytoid DCs have been referred to as tolerogenic under certain circumstances and produce large amounts of IFN-α, which inhibits cell proliferation (52). Thus, the increased number of plasmacytoid DCs may help to limit the consequence of the absence of LAG-3.

Although there was clearly an increased number of T cells in spleen and Peyer’s patch, this difference was not seen in lymph nodes or bone marrow. The significance of this intriguing finding is unclear. It is conceivable that bone marrow and lymph nodes only contain T cells that are in transit and thus are less affected by the absence of LAG-3. In contrast, spleen and Peyer’s patch have more resident T cells that are not migrating and thus can accumulate as a consequence of homeostatic deregulation. Our data may indicate that the contributions of different organs to homeostatic regulation are distinct, and as such, LAG-3$^{-/-}$ mice may represent a very useful model to dissect this issue further.

It is intriguing that a molecule that binds to MHC class II regulates both CD4$^+$ and CD8$^+$ T cell homeostasis. Our data imply a requirement for LAG-3:MHC class II ligation in vivo to regulate homeostatic expansion. Is the restricted expression of MHC class II important for the consequences of LAG-3 function? It is likely that in lymphoid organs or other sites where a high number of MHC class II$^+$ B cells or DCs are present, T cell expansion would be controlled by LAG-3. However, in instances where T cells would normally undergo homeostatic expansion, such as in neonates (8), MHC class II$^+$ cells would also be largely absent, thus allowing for the discriminatory use of LAG-3.

Hematopoietic stem cell and bone marrow transplantation are becoming standard therapies in the treatment of both malignant and nonmalignant disorders (53). However, for patients that receive myeloablative conditioning, there is a long period of profound immunodeficiency that can result in significant complications and mortality. Full T cell reconstitution can take >1 year for autologous bone marrow transplantation (53, 54). Some peripheral expansion of transplanted donor T cells in the graft occurs in the first few months and provides some level of protection (55, 56). However, de novo generation of thymus-derived T cells is known to be essential for complete immunocompetence (57, 58). Any therapeutic intervention that leads to accelerated T cell reconstitution could have significant clinical benefits. Our data suggest that interfering with LAG-3 function could be a legitimate target. Indeed, our data show that in vivo treatment with anti-LAG-3 mAb resulted in accelerated T cell expansion (Fig. 3B). Data from this study also suggest that LAG-3 is required for $T_{reg}$ cell control of homeostasis, suggesting that LAG-3 modulation may be used to enhance or abrogate $T_{reg}$ cell activity. Identification of additional molecules that negatively regulate lymphocyte homeostasis will be important in furthering our understanding of this essential, biological process and in providing additional targets for therapeutic intervention.

Acknowledgments

We are very grateful to Yao Wang and Kari Dugger for technical assistance, to Richard Cross and Jennifer Hoffrage for FACS, to the staff of the flow cytometry and cell sorting shared resource facility for MACS sorting, and to Drew Pardoll for constructive comments on the manuscript.

References
